Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

被引：2
|
作者：
Bertoli, Sarah [1 ]
Gadaud, Noemie [2 ]
Tavitian, Suzanne [1 ]
Sarry, Audrey [1 ]
Berard, Emilie [3 ,4 ]
Huguet, Francoise [1 ]
Recher, Christian [1 ,5 ]
机构：
[1] CHU Toulouse, Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France
[2] Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France
[3] CHU Toulouse, Serv Epidemiol, Toulouse, France
[4] Univ Toulouse 3, INSERM, UMR 1027, Toulouse, France
[5] CNRS, ERL5294, INSERM, UMR1037,Ctr Rech Cancerol Toulouse, Toulouse, France
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3991.3991
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3991
引用
收藏
页数：5
相关论文
共 50 条
  • [41] COMBINATION OF CLOFARABINE AND CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
    Spassov, B.
    Balatzenko, G.
    Angelova, S.
    Toshkov, S.
    Guenova, M.
    Arnaudov, G.
    Mihaylov, G.
    HAEMATOLOGICA, 2015, 100 : 377 - 377
  • [42] Cytarabine in relapsed acute myeloid leukemia
    Hardesty, Brandon M.
    Cripe, Larry D.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 387 - 388
  • [43] Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia
    Saito, Bungo
    Nakamaki, Tsuyoshi
    Nakashima, Hidetoshi
    Usui, Takako
    Hattori, Norimichi
    Kawakami, Keiichiro
    Tomoyasu, Shigeru
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (04) : 304 - 306
  • [44] Extended study for topotecan, idarubicin, and intermediate-dose cytarabine combination chemotherapy in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Kim, Y
    Cheong, JW
    Kim, JS
    Park, IH
    Park, SY
    Lee, ST
    Min, YH
    BLOOD, 2005, 106 (11) : 231B - 231B
  • [45] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [46] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Zucenka, Andrius
    Maneikis, Kazimieras
    Pugaciute, Birute
    Ringeleviciute, Ugne
    Dapkeviciute, Austeja
    Davainis, Linas
    Daukelaite, Guoda
    Burzdikaite, Paulina
    Staras, Vytautas
    Griskevicius, Laimonas
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1195 - 1202
  • [47] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Andrius Zucenka
    Kazimieras Maneikis
    Birute Pugaciute
    Ugne Ringeleviciute
    Austeja Dapkeviciute
    Linas Davainis
    Guoda Daukelaite
    Paulina Burzdikaite
    Vytautas Staras
    Laimonas Griskevicius
    Annals of Hematology, 2021, 100 : 1195 - 1202
  • [48] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    Ji-hao Zhou
    Hai-qing Lin
    Qi Shen
    Li-na Hu
    Guo-qiang Li
    Xiong-fei Sun
    Xin-you Zhang
    Current Medical Science, 2018, 38 : 51 - 57
  • [49] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    Zhou, Ji-hao
    Lin, Hai-qing
    Shen, Qi
    Hu, Li-na
    Li, Guo-qiang
    Sun, Xiong-fei
    Zhang, Xin-you
    CURRENT MEDICAL SCIENCE, 2018, 38 (01) : 51 - 57
  • [50] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    周继豪
    林海清
    沈琦
    胡丽娜
    李国强
    孙雄飞
    张新友
    Current Medical Science, 2018, (01) : 51 - 57
12345